PlainRecalls
FDA Drug Moderate Class II Terminated

Ramipril Capsules USP 2.5 mg, a) 90 count (NDC 68180-589-09), b) 100 count NDC 68180-589-01), and c) 500 count (NDC 68180-589-02) bottles, Rx only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, Manufactured by Lupin Limited, Goa, India

Reported: November 27, 2024 Initiated: October 23, 2024 #D-0052-2025

Product Description

Ramipril Capsules USP 2.5 mg, a) 90 count (NDC 68180-589-09), b) 100 count NDC 68180-589-01), and c) 500 count (NDC 68180-589-02) bottles, Rx only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, Manufactured by Lupin Limited, Goa, India

Reason for Recall

CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor

Details

Units Affected
112,770 bottles
Distribution
Product was distributed to 30 wholesalers/distributors who may have further distributed the product nationwide.
Location
Baltimore, MD

Frequently Asked Questions

What product was recalled?
Ramipril Capsules USP 2.5 mg, a) 90 count (NDC 68180-589-09), b) 100 count NDC 68180-589-01), and c) 500 count (NDC 68180-589-02) bottles, Rx only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, Manufactured by Lupin Limited, Goa, India. Recalled by Lupin Pharmaceuticals Inc.. Units affected: 112,770 bottles.
Why was this product recalled?
CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor
Which agency issued this recall?
This recall was issued by the FDA Drug on November 27, 2024. Severity: Moderate. Recall number: D-0052-2025.